Skip to main content

Table 3 Association between methylation patterns of MLH1 and MGMT and mutational status

From: Correlation of MLH1 and MGMTexpression and promoter methylation with genomic instability in patients with thyroid carcinoma

Methylation status Mutational status N (%) p
BRAF V600E*
MLH1 Methylated Positive 4/20 (20%) 0.048
   Negative 10/19 (53%)  
  Unmethylated Positive 16/20 (80%)  
   Negative 9/19 (47%)  
MGMT Methylated Positive 14/20 (70%) 0.333
   Negative 10/19 (53%)  
  Unmethylated Positive 6/20 (30%)  
   Negative 9/19 (47%)  
RET/PTC*
MLH1 Methylated Positive 8/16 (50%) 1.000
   Negative 10/19 (53%)  
  Unmethylated Positive 8/16 (50%)  
   Negative 9/19 (47%)  
MGMT Methylated Positive 9/16 (56%) 1.000
   Negative 10/19 (53%)  
  Unmethylated Positive 7/16 (44%)  
   Negative 9/19 (47%)  
Transitions (IDH1 + NRAS)
MLH1 Methylated Positive 5/11 (45%) 1.000
   Negative 13/25 (52%)  
  Unmethylated Positive 6/11 (55%)  
   Negative 12/25 (48%)  
MGMT Methylated Positive 9/11 (82%) 0.268
   Negative 15/25 (60%)  
  Unmethylated Positive 2/11 (18%)  
   Negative 10/25 (40%)  
Point mutations (BRAF + IDH1 + NRAS)
MLH1 Methylated Positive 14/41 (34%) 0.199
   Negative 13/25 (52%)  
  Unmethylated Positive 27/41 (66%)  
   Negative 12/25 (48%)  
MGMT Methylated Positive 29/41 (71%) 0.426
   Negative 15/25 (60%)  
  Unmethylated Positive 12/41 (29%)  
   Negative 10/25 (40%)  
  1. * Analysis performed only in the PTC group.
  2. Negative group comprises only samples without any of the alterations investigated.